Review of Contemporary Philosophy
ISSN: 1841-5261, e-ISSN: 2471-089X
Vol 22 (1), 2023
Pp 5589 - 5595

Cerebral Salt Wasting Syndrome-A Central Nervous Disorders: Diagnosis, Management, And Treatment

[1]-Sakinah Muneer Al Sharaf ,[2]-Fawaz Abdulrahman Abdullah Altayash,[3]-Raed Muawwad Aifan Al Fizzi ,[4]-Mohammed Saad Almugahwi,[5]-Haya Farhan Alenazi,[6]-Hayat Gazy Khormi,[7]- Falah Falih Alsahali

[1] KSA, Ministry of Health, Al Rafee'ah General Hospital
[2] KSA, Ministry of Health, King saud medical city
[3] KSA, Ministry of Health, King Fahd General Hospital in Jeddah
[4] KSA, Ministry of Health, Community Health in the Health Cluster in Al-Ahsa Governorate
[5] Environmental Health and Occupational Health
[6] KSA, Ministry of Health, Prince Mohammed bin abduaziz hospital
[7] KSA, Ministry of Health, Abu Arish General Hospital
[8] Ksa, Ministry Of Health, Hotat Sudir Hospital

Abstract:

Background: Cerebral Salt Wasting Syndrome (CSW) is a condition often associated with central nervous system (CNS) disorders, characterized by hyponatremia, hypovolemia, and elevated urinary sodium excretion. Its differentiation from Syndrome of Inappropriate Antidiuretic Hormone (SIADH) is critical due to opposing management strategies.

Aim: This article aims to explore the diagnosis, management, and treatment of CSW, emphasizing its pathophysiology, clinical features, and therapeutic approaches.

Methods: A review of current literature and case studies was conducted, focusing on CSW's epidemiology, pathophysiology, diagnostic criteria, and treatment protocols.

Results: CSW is most commonly observed in cases of aneurysmal subarachnoid hemorrhage, with other triggers including CNS surgeries, infections, and malignancies. Pathophysiological mechanisms involve hypothalamic dysfunction and the release of brain natriuretic peptide, leading to excessive natriuresis and hypovolemia. Diagnostic criteria include distinguishing features of hypovolemia and laboratory findings such as low serum sodium and high urinary sodium levels. Management entails fluid and sodium supplementation, with isotonic or hypertonic saline being common treatments.

Conclusion: CSW remains a diagnostic and therapeutic challenge due to its overlap with SIADH. Early recognition and accurate differentiation are essential for effective management, preventing complications such as neurological damage or exacerbated electrolyte imbalances. Further research into its pathophysiology may provide insights for targeted interventions.

Keywords: Cerebral salt wasting, hyponatremia, central nervous system disorders, diagnosis, treatment, brain natriuretic peptide, hypovolemia

Received: 05 October 2023 **Revised**: 19 November 2023 **Accepted**: 02 December 2023

Introduction:

Cerebral salt wasting (CSW) is a condition frequently observed in the context of central nervous system (CNS) disorders and is characterized by hyponatremia, elevated urinary sodium excretion, and hypovolemia. Despite being recognized for decades, debates persist regarding its classification as an independent clinical entity or a subtype of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). This distinction is critical because the management of CSW and SIADH involves diametrically

opposing therapeutic strategies. CSW requires fluid and sodium supplementation to address the hypovolemia and restore electrolyte balance, whereas SIADH necessitates fluid restriction to prevent fluid overload. The pathophysiology of CSW is complex and not entirely understood. Two prevailing theories have been proposed: one suggests that injury to the CNS leads to the release of brain natriuretic peptide (BNP), which disrupts sodium balance by reducing its reabsorption in renal tubules and inhibiting renin release. The other implicates hypothalamic damage and subsequent dysfunction of the sympathetic nervous system, resulting in impaired sodium retention. CSW typically resolves within weeks to months, but chronic cases have been reported, highlighting the necessity for vigilant long-term management. Failure to accurately diagnose and differentiate CSW from SIADH or other hyponatremic conditions can lead to inappropriate treatment, worsening the patient's clinical condition. Therefore, a high degree of clinical suspicion, coupled with a thorough understanding of its pathophysiology and management principles, is essential for optimizing outcomes [1].

Etiology

The exact etiology of cerebral salt wasting (CSW) remains incompletely understood, although it is commonly associated with CNS insults. Aneurysmal subarachnoid hemorrhage is the most frequently documented precipitant, accounting for a significant proportion of cases. Interestingly, CSW appears to occur more frequently in aneurysmal subarachnoid hemorrhage than in other types of CNS injury, such as traumatic subarachnoid hemorrhage. This observation suggests that specific pathophysiological mechanisms may be triggered uniquely in certain types of CNS damage. Other reported triggers include surgeries involving the CNS, such as procedures for pituitary tumors, vestibular schwannomas, or calvarial remodeling. Additionally, infections like tuberculous meningitis, viral meningitis, and certain intracranial malignancies have been associated with CSW. The condition has also been documented following cranial trauma, although its occurrence in such contexts is less common. The underlying mechanisms linking these diverse triggers to CSW are not well understood, necessitating further research to elucidate causative pathways. The variability in precipitating factors underscores the need for clinicians to maintain a broad differential diagnosis when evaluating patients with hyponatremia and CNS pathology. While the etiology of CSW may be elusive in some cases, recognizing common triggers and understanding their potential impact on fluid and electrolyte homeostasis are essential for early diagnosis and management.

Epidemiology

The epidemiology of cerebral salt wasting (CSW) is not clearly defined due to the ongoing debate regarding its classification and diagnostic criteria. Despite these challenges, certain trends have been identified. CSW is most frequently reported in patients with aneurysmal subarachnoid hemorrhage, where it accounts for an estimated 25% of severe hyponatremia cases. Beyond this context, CSW has been documented in a variety of other CNS-related conditions, including surgeries for pituitary tumors, acoustic neuromas, and cranial trauma. Infections such as tuberculous and viral meningitis, as well as intracranial malignancies and metastatic carcinomas, have also been implicated as potential triggers. However, its prevalence outside the setting of CNS insults remains unclear, with most reported cases arising from isolated case reports. This lack of comprehensive epidemiological data is further compounded by the overlap between CSW and other causes of hyponatremia, particularly SIADH, which can confound diagnostic accuracy. Establishing a reliable prevalence rate is critical for understanding the condition's burden and informing clinical practice. This underscores the importance of developing standardized diagnostic criteria and enhancing awareness among healthcare providers. Epidemiological studies focusing on the incidence of CSW in diverse patient populations are necessary to fill existing gaps in knowledge and provide a more comprehensive understanding of its clinical relevance.

Pathophysiology

The pathophysiology of cerebral salt wasting (CSW) remains a contentious and evolving area of study. Two primary mechanisms have been proposed to explain its occurrence: the influence of a circulating factor and dysfunction of the sympathetic nervous system. The first theory posits that CNS injuries trigger the release of brain natriuretic peptide (BNP) into systemic circulation, potentially facilitated by a disrupted blood-

brain barrier. BNP exerts its effects on renal tubules by inhibiting sodium reabsorption and reducing renin release, leading to excessive natriuresis and hyponatremia. The second theory highlights hypothalamic damage as a pivotal factor, which disrupts the regulatory functions of the sympathetic nervous system. This disruption impairs sodium retention and diminishes the release of renin, further exacerbating sodium loss. Both theories provide plausible explanations for the observed clinical and biochemical features of CSW; however, definitive evidence to validate either hypothesis remains elusive. Additionally, the overlap in clinical presentation and laboratory findings with conditions like SIADH complicates the pathophysiological understanding of CSW. Continued research is necessary to delineate the precise mechanisms underlying this condition, which may have significant implications for its diagnosis and management. Identifying the exact pathways involved could also pave the way for targeted therapeutic interventions aimed at mitigating the impact of CSW on patients with CNS injuries.

History and Physical

The clinical presentation of cerebral salt wasting (CSW) is often heralded by the development of hyponatremia, particularly following aneurysmal subarachnoid hemorrhage. This typically occurs a few days after the initial CNS insult, with patients exhibiting a progressive decline in serum sodium levels, accompanied by increased urinary sodium excretion. Symptoms of hypovolemia, such as hypotension, poor skin turgor, and reduced central venous pressure, are hallmarks of the condition. These features differentiate CSW from other causes of hyponatremia, such as SIADH, where patients are typically euvolemic or hypervolemic. Beyond subarachnoid hemorrhage, CSW has been reported in various clinical scenarios, including CNS surgeries (e.g., pituitary tumor resection, calvarial remodeling), intracranial malignancies, cranial trauma, and CNS infections. The condition is often self-limited, resolving within weeks to months; however, prompt recognition and appropriate management are crucial to prevent complications related to severe hyponatremia and hypovolemia. Long-term treatment is rarely required, but close monitoring during the acute phase is essential to ensure optimal outcomes.

Evaluation

Evaluating cerebral salt wasting (CSW) involves distinguishing it from other causes of hyponatremia, particularly the syndrome of inappropriate secretion of antidiuretic hormone (SIADH), due to their opposing management strategies. Diagnostic evaluation begins with laboratory tests, including a basic metabolic panel to confirm hyponatremia (serum sodium <135 mEq/L). Urine studies reveal elevated sodium levels (>40 mEq/L) and increased osmolality (>100 mOsm/kg), consistent with natriuresis. Clinical assessment identifies signs of hypovolemia, such as hypotension, reduced skin turgor, and elevated hematocrit, which are characteristic of CSW. In contrast, patients with SIADH present with euvolemia or hypervolemia due to water retention. Exclusion of other potential causes of hyponatremia, such as renal disease, polydipsia, diuretics, and hormonal deficiencies, is essential for an accurate diagnosis. Often, CSW becomes a diagnosis of exclusion following comprehensive evaluation. Advanced diagnostic tools, including imaging studies and specialized assays, may aid in distinguishing CSW from overlapping conditions. Accurate diagnosis is critical for implementing appropriate therapeutic interventions and improving patient outcomes [3][4].

Treatment / Management

The management of cerebral salt wasting (CSW) and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) requires precise diagnosis due to the significant differences in treatment approaches. Misdiagnosis can lead to inappropriate interventions, potentially worsening the patient's condition. CSW frequently occurs following aneurysmal subarachnoid hemorrhage. Therefore, initial management targets the underlying cause, such as addressing the subarachnoid hemorrhage and aneurysmal complications or other central nervous system (CNS) insults. These foundational treatments are elaborated in discussions about acute subarachnoid hemorrhage. Concurrently, the patient's hypovolemia and hyponatremia must be addressed. In mild to moderate cases, isotonic saline is commonly used to restore both intravascular volume and sodium balance. For more severe hyponatremia, aggressive sodium repletion may be necessary. This may involve administering hypertonic saline (e.g., 3%) and/or

sodium chloride tablets (1–2 grams up to three times daily), coupled with restricted free water intake. Some clinicians advocate for fludrocortisone to enhance sodium retention [4]. Frequent monitoring of serum sodium levels is critical during treatment. Rapid or excessive correction can lead to hypernatremia, associated with symptoms such as muscle twitching, seizures, lethargy, or fatal outcomes. Furthermore, rapid correction of long-standing hyponatremia may result in central pontine myelinolysis, a potentially irreversible neurological complication. Experts recommend maintaining sodium correction below 10 meq/L over 24 hours or 1 meq/L every 2 hours to minimize risks. Differentiating CSW from SIADH is paramount, as their treatments are diametrically opposed. While CSW management focuses on volume repletion, SIADH treatment typically involves fluid restriction, hypertonic saline, demeclocycline, or furosemide. In cases of misdiagnosed SIADH, employing these strategies in a patient with true CSW can exacerbate hypovolemia, with potentially dangerous consequences [5][6][7].

Differential Diagnosis

The differentiation between cerebral salt wasting (CSW) and syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is essential due to overlapping clinical features such as hyponatremia, elevated urine sodium levels, concentrated urine, and absence of edema. However, the defining characteristic lies in the patient's volume status: CSW is associated with hypovolemia, whereas SIADH presents with euvolemia to hypervolemia [3]. The etiological spectrum of CSW includes various CNS pathologies. Traumatic head injuries and brain tumors are among the most common causes. Other conditions include cerebrovascular events such as strokes, intracranial surgeries, and intracerebral hemorrhages. Additional causes encompass craniosynostosis repair and infections like tuberculous meningitis. Understanding these etiologies facilitates early identification and targeted management of the condition.

Enhancing Healthcare Team Outcomes

Effective management of cerebral salt wasting (CSW), particularly after significant CNS insults such as aneurysmal subarachnoid hemorrhage, demands a coordinated interprofessional approach. The complexity of treatment requires careful fluid management to avoid complications such as cerebral edema, pulmonary edema, heart failure, or renal dysfunction. Clinicians must exercise caution in administering free water via carrier fluids for medications, as excessive free water can exacerbate hyponatremia. Management of hyponatremia may extend for weeks to months, necessitating continuous monitoring of the patient's Glasgow Coma Scale (GCS) and neurological status. While the prognosis for CSW not associated with subarachnoid hemorrhage is generally favorable, some patients may experience persistent mild neurological deficits despite optimal care [8][9]. An interprofessional healthcare team enhances outcomes significantly. Primary care physicians, emergency physicians, neurologists, and neurosurgeons collaborate with critical care and neuroscience nurses to monitor, educate, and provide updates on patient progress. Specialty care nurses play a vital role in administering treatments, monitoring neurological signs, and supporting patient and family education. Pharmacists contribute by reviewing prescribed medications, identifying potential drug interactions, and recommending therapeutic adjustments to the clinical team as necessary. Such a coordinated approach ensures that patients receive comprehensive care tailored to their specific needs, ultimately improving long-term outcomes.

Hyponatremia and the Role of AVP Secretion:

Hyponatremia, regardless of its attribution to cerebral salt wasting (CSW) or syndrome of inappropriate antidiuretic hormone secretion (SIADH), arises from the nonosmotic secretion of arginine vasopressin (AVP). In CSW, AVP secretion represents an appropriate physiological reaction to volume depletion, whereas in SIADH, its secretion is pathological. AVP-secreting neurons are influenced by two primary afferent inputs: osmotic signals from osmoreceptor neurons responsive to plasma tonicity, indirectly reflecting serum sodium (SNa), and nonosmotic signals from baroreceptors that detect effective arterial blood volume (EABV). When AVP secretion is stimulated by low EABV or inhibited by low SNa, it is deemed appropriate. In hyponatremic patients with reduced EABV, baroreceptor signals override osmoreceptor inhibition, promoting AVP secretion despite reduced SNa. Restoration of EABV reverses this process,

allowing osmoreceptor-mediated inhibition to suppress AVP secretion. Clinically, AVP levels are challenging to measure due to the requirement for specialized research laboratory methods. Consequently, clinicians depend on urine osmolality (UOsm) as a surrogate marker for AVP activity. In cases of hyponatremia and euvolemia with suppressed AVP, urine should exhibit maximum dilution, characterized by UOsm values below 100 mOsm/kg, often reaching as low as 50 mOsm/kg. Conversely, in the presence of UOsm values exceeding 100 mOsm/kg, AVP likely contributes to hyponatremia. Sodium excretion in hyponatremic states aligns with changes in EABV, which integrates extracellular fluid volume, cardiac output, and vascular tone. While an expanded EABV augments sodium excretion, a contracted EABV restricts it. In SIADH-related hyponatremia, AVP secretion persists without a physiological osmotic or hemodynamic stimulus, resulting in sodium loss that subsides upon resolving hyponatremia via water restriction. In contrast, CSW-induced hyponatremia originates from sodium loss as the primary defect, with AVP secretion driven by hypovolemia, ceasing upon volume restoration.

Evidentiary Challenges in Confirming Hyponatremia due to CSW:

Establishing that hyponatremia is attributable to hypovolemia-induced AVP secretion necessitates demonstrating that AVP can be suppressed following volume repletion. Patients with hypovolemic hyponatremia caused by extrarenal sodium losses, diuretic use, or renal salt-wasting disorders (e.g., those induced by cisplatin or Addison's disease) typically exhibit prompt urine dilution (UOsm <100 mOsm/kg) and rapid SNa correction upon volume restoration. However, transient SIADH states (e.g., following surgical procedures, infections, nausea, or medications) may also result in similar urine dilution post-recovery. To differentiate between CSW and transient SIADH, persistent salt-wasting evidence is essential. Effective volume restoration should eliminate hypovolemic symptoms, decrease hematocrit levels, and result in maximally diluted urine. Subsequently, the discontinuation of isotonic saline should lead to hyponatremia recurrence, accompanied by concentrated urine, high sodium excretion rates, weight reduction, increased hematocrit, and re-emergence of hypovolemic signs. Despite extensive literature on CSW, evidence substantiating its existence remains inadequate. Much of the reported data are reliant on criteria fraught with limitations. For instance, findings such as hypovolemia on physical examination, reduced red blood cell (RBC) mass, or plasma volume, and negative sodium balance lack specificity and sensitivity. Similarly, observations such as an increase in SNa in response to isotonic saline, reduction in UOsm below serum osmolality, or elevated fractional excretion of uric acid (FEurate) after hyponatremia correction fail to conclusively differentiate CSW from SIADH. Consequently, these criteria, while indicative, are not definitive in confirming CSW [10].

Role of Pharmacists in Management and Treatment of Cerebral Salt Wasting Syndrome:

Cerebral Salt Wasting Syndrome (CSWS) is a rare but significant cause of hyponatremia, particularly in patients with neurological conditions such as traumatic brain injury, subarachnoid hemorrhage, or central nervous system infections. It is characterized by excessive renal sodium loss, leading to extracellular fluid depletion. Managing CSWS involves a multidisciplinary approach, where pharmacists play a crucial role in optimizing therapeutic outcomes through their expertise in pharmacotherapy, patient education, and interdisciplinary collaboration.

Identification and Monitoring

Pharmacists are pivotal in the early identification and monitoring of CSWS by analyzing laboratory results, including serum sodium levels, urine sodium concentrations, and fluid balance. They work closely with physicians to differentiate CSWS from other causes of hyponatremia, such as Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH), which requires different treatment strategies. By ensuring accurate interpretation of diagnostic markers, pharmacists help guide timely and appropriate interventions.

Pharmacotherapy Optimization

The primary goal in managing CSWS is to restore sodium and fluid balance while addressing the underlying neurological condition. Pharmacists contribute by recommending and dosing hypertonic saline solutions

to correct severe hyponatremia and replenish extracellular fluid. They ensure the careful titration of fluids to avoid rapid sodium correction, which can lead to complications such as osmotic demyelination syndrome. Additionally, in cases requiring mineralocorticoid therapy, such as fludrocortisone, pharmacists provide insights into the drug's benefits and potential adverse effects. Fludrocortisone enhances sodium reabsorption in the renal tubules, and its administration must be monitored for risks like hypertension and hypokalemia. Pharmacists play an integral role in evaluating patient-specific factors to tailor therapy, optimizing the balance between efficacy and safety.

Interdisciplinary Collaboration

Pharmacists are essential members of the healthcare team in CSWS management. They collaborate with physicians, nurses, and dietitians to develop comprehensive care plans, ensuring that sodium supplementation and fluid management align with the patient's overall clinical condition. By participating in case discussions, pharmacists contribute to evidence-based decision-making and enhance the quality of care.

Patient and Caregiver Education

Patient and caregiver education is another critical component of the pharmacist's role. They provide clear instructions on recognizing signs of hyponatremia and adhering to prescribed therapies, including fluid intake and medication regimens. Pharmacists also educate patients on potential side effects of medications, promoting adherence and early detection of complications.

Research and Policy Development

Pharmacists contribute to advancing the understanding of CSWS by participating in research initiatives and clinical trials aimed at evaluating new treatment modalities. Their involvement in developing institutional guidelines and protocols for managing hyponatremia ensures that best practices are implemented consistently across healthcare settings. Pharmacists are integral to the management of CSWS, offering expertise in diagnosis, therapeutic interventions, patient education, and interdisciplinary collaboration. By optimizing pharmacotherapy, ensuring safe and effective treatment strategies, and engaging in ongoing research, pharmacists enhance patient outcomes and contribute to the overall quality of care for individuals with this challenging condition.

Conclusion:

Cerebral Salt Wasting Syndrome (CSW) is a complex clinical entity that poses significant diagnostic and therapeutic challenges, particularly due to its overlap with other hyponatremic conditions such as Syndrome of Inappropriate Antidiuretic Hormone (SIADH). The condition is most frequently linked to CNS insults, notably aneurysmal subarachnoid hemorrhage, but can also arise from CNS surgeries, infections, malignancies, and cranial trauma. Understanding the underlying mechanisms of CSW is crucial for accurate diagnosis and management. The pathophysiology of CSW primarily involves hypothalamic dysfunction and the release of brain natriuretic peptide, leading to excessive sodium loss and hypovolemia. This distinct feature differentiates from SIADH, which is characterized by euvolemia or hypervolemia. The diagnostic process requires a thorough clinical evaluation, focusing on volume status, serum sodium levels, and urinary sodium excretion, coupled with the exclusion of other potential causes of hyponatremia. Management strategies for CSW revolve around restoring intravascular volume and correcting sodium deficits. Isotonic or hypertonic saline and sodium chloride tablets are commonly used, along with fludrocortisone in severe cases to enhance sodium retention. However, clinicians must exercise caution to avoid rapid correction of sodium levels, which could result in complications such as central pontine myelinolysis or hypernatremia. The importance of frequent monitoring during treatment cannot be overstated, as it ensures the safety and effectiveness of therapeutic interventions. Differentiating CSW from SIADH is vital, as their management strategies are diametrically opposed. Misdiagnosis can lead to inappropriate treatment, worsening the patient's condition. An interprofessional approach involving neurologists, intensivists, and nephrologists is essential to optimize outcomes and reduce the risk of complications. Further research is needed to elucidate the exact pathophysiological mechanisms

underlying CSW and to develop standardized diagnostic criteria. Such advancements would significantly enhance the understanding and management of this challenging condition, improving patient care and clinical outcomes.

References:

1. Leonard J, Garrett RE, Salottolo K, Slone DS, Mains CW, Carrick MM, Bar-Or D. Cerebral salt wasting after traumatic brain injury: a review of the literature. Scand J Trauma Resusc Emerg Med. 2015 Nov 11;23:98.
2. Cerdà-Esteve M, Cuadrado-Godia E, Chillaron JJ, Pont-Sunyer C, Cucurella G, Fernández M, Goday A, Cano-Pérez JF, Rodríguez-Campello A, Roquer J. Cerebral salt wasting syndrome: review. Eur J Intern Med. 2008 Jun;19(4):249-54.
3. Oh JY, Shin JI. Syndrome of inappropriate antidiuretic hormone secretion and cerebral/renal salt wasting syndrome: similarities and differences. Front Pediatr. 2014;2:146.
4. Yee AH, Burns JD, Wijdicks EF. Cerebral salt wasting: pathophysiology, diagnosis, and treatment. Neurosurg Clin N Am. 2010 Apr;21(2):339-52.
5. Jin S, Long Z, Wang W, Jiang B. Hyponatremia in neuromyelitis optica spectrum disorders: Literature review. Acta Neurol Scand. 2018 Jul;138(1):4-11.
6. Moritz ML. Syndrome of Inappropriate Antidiuresis. Pediatr Clin North Am. 2019 Feb;66(1):209-226.
7. Maesaka JK, Imbriano LJ, Miyawaki N. High Prevalence of Renal Salt Wasting Without Cerebral Disease as Cause of Hyponatremia in General Medical Wards. Am J Med Sci. 2018 Jul;356(1):15-22.
8. John CA, Day MW. Central neurogenic diabetes insipidus, syndrome of inappropriate secretion of antidiuretic hormone, and cerebral salt-wasting syndrome in traumatic brain injury. Crit Care Nurse. 2012 Apr;32(2):e1-7; quiz e8.
9. Rahman M, Friedman WA. Hyponatremia in neurosurgical patients: clinical guidelines development. Neurosurgery. 2009 Nov;65(5):925-35; discussion 935-6.
10. Tenny, S., & Thorell, W. (2023). Cerebral salt wasting syndrome. In *StatPearls [Internet]*. StatPearls Publishing.

متلازمة فقدان الملح الدماغية - اضطرابات الجهاز العصبي المركزي: التشخيص والإدارة والعلاج

الملخص:

الخلفية :تُعتبر متلازمة فقدان الملح الدماغية (CSW) حالة تُرافق غالباً اضطرابات الجهاز العصبي المركزي(CNS) ، وتتميز بنقص صوديوم الدم، ونقص حجم الدم، وزيادة إفراز الصوديوم في البول. يُعد التمييز بينها وبين متلازمة الإفراز غير المناسب للهرمون المضاد لإدرار البول (SIADH) أمراً حاسماً نظراً لاستراتيجيات الإدارة المتعارضة بينهما.

الهدف :تهدف هذه المقالة إلى استكشاف تشخيص وإدارة وعلاج متلازمة فقدان الملح الدماغية، مع التركيز على الفيزيولوجيا المرضية والخصائص السريرية والنهج العلاجية.

الطرق :تم إجراء مراجعة للأدبيات الحالية ودراسات الحالة، مع التركيز على علم الأوبئة، والفيزيولوجيا المرضية، والمعايير التشخيصية، وبروتوكولات العلاج المتعلقة بمتلازمة فقدان الملح الدماغية.

النتائج :تُلاحظ متلازمة فقدان الملح الدماغية بشكل شائع في حالات النزف تحت العنكبوتي الناتج عن تمدد الأوعية الدموية، مع وجود محفزات أخرى تشمل جراحات الجهاز العصبي المركزي، والالتهابات، والأورام الخبيثة. تتضمن الآليات الفيزيولوجية المرضية خللاً في وظيفة تحت المهاد وإفراز الببتيد الناتريوتريكي الدماغي، مما يؤدي إلى زيادة إفراز الصوديوم ونقص حجم الدم. وتشمل المعايير التشخيصية خصائص مميزة مثل نقص حجم الدم والنتائج المختبرية كارتفاع مستويات الصوديوم في البول وانخفاض صوديوم الدم. تعتمد الإدارة على تعويض السوائل والصوديوم باستخدام المحاليل الملحية المتساوية أو عالية التوتر.

الخاتمة :تظل متلازمة فقدان الملح الدماغية تحدياً تشخيصياً وعلاجياً نظراً لتداخلها مع متلازمة الإفراز غير المناسب للهرمون المضاد لإدرار البول. يُعد التعرف المبكر والتمييز الدقيق أمراً ضرورياً للإدارة الفعالة والوقاية من المضاعفات مثل الأضرار العصبية أو تفاقم اختلال توازن الإلكتروليتات. قد يساهم البحث المستقبلي في فهم الفيزيولوجيا المرضية بشكل أعمق، مما يوفر رؤى للتدخلات المستهدفة.

الكلمات المفتاحية :متلازمة فقدان الملح الدماغية، نقص صوديوم الدم، اضطرابات الجهاز العصبي المركزي، التشخيص، العلاج، الببتيد الناتريوتريكي الدماغي، نقص حجم الدم.